All In Biotech

Drug Trial Radar · NCT05882734

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

An Open Label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR Inhibitor M1774 in Combination With Cemiplimab in Participants With Non-Squamous Non-Small Cell Lung Cancer That Has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies (DDRiver NSCLC 322)

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

61

Actual

Start

Sep 13, 2023

Primary completion

Jul 15, 2026

Study completion Jul 15, 2026

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
May 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • M1774Drug

    In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.

  • CemiplimabDrug

    Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b/Phase 2a: Confirmed Overall response (OR) According to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 As assessed by InvestigatorTime frame: Time from randomization to final assessment or until progression disease, death, discontinuation criteria approximately up to 3 years and 2 months
  2. Phase 1b: Number of Participants With Adverse Events (AEs) and Treatment-related AEsTime frame: Time from randomization to final assessment at end of safety follow-up visit approximately up to 3 years and 2 months

Locations

54 sites in 8 countries. Site status is shown where the registry gives one.

  • UCLA Hematology and Oncology - Santa Monica

    Santa Monica, California

  • UPMC Cancer Center

    Pittsburgh, Pennsylvania

  • Tennessee Cancer Specialists - Biomedical Research

    Knoxville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Millennium Research & Clinical Development

    Houston, Texas

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Institut Jules Bordet - Department of Institut Jules Bordet'

    Anderlecht, Belgium

  • UZA - Oncology

    Edegem, Belgium

  • Jessa Ziekenhuis Hospital

    Hasselt, Belgium

  • Universitair Ziekenhuis Brussel - UZB

    Jette, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHU de Liège - PARENT

    Liège, Belgium

  • CHU Angers - Hôpital Larrey - Service de Pneumologie

    Angers, France

  • Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie

    Créteil, France

  • CHU Limoges - Hôpital Dupuytren - Unite d'Oncologie Thoracique et Cutanée

    Limoges, France

  • Hôpital de la Timone - CPCEM CIC - Bat F 1er étage

    Marseille, France

  • Hopital Arnaud de Villeneuve - Service de Pneumologie-Addictologie

    Montpellier, France

  • Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Unité d'Explorations Fonctionnelles Respiratoires

    Pessac, France

  • ICO - Site René Gauducheau - Service d'Oncologie medicale

    Saint-Herblain, France

  • Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik und Poliklinik III

    Giessen, Germany

  • Universitaetsklinikum Leipzig AoeR - Med. Klinik u. Poliklinik I - Abt. Pneumologie

    Leipzig, Germany

  • Sana Klinikum Offenbach GmbH - Medizinische Klinik IV

    Offenbach, Germany

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS - U.O. Oncologia Medica

    Bologna, Italy

  • IEO Istituto Europeo di Oncologia - Divisione Oncologia Medica

    Milan, Italy

  • Ospedale San Raffaele - U.O. di Oncologia Medica

    Milan, Italy

  • Istituto Nazionale Tumori Fondazione G. Pascale - Medical Oncology Thoraco-Pulmonary Department

    Naples, Italy

  • Istituto Nazionale Tumori Regina Elena IRCCS - S.C. Oncologia Medica B

    Roma, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica

    Rome, Italy

  • Istituto Clinico Humanitas - U.O. di Oncologia Medica ed Ematologia

    Rozzano, Italy

  • National Cancer Center Hospital

    Chūōku, Japan

  • Kansai Medical University Hospital

    Hirakata-shi, Japan

  • National Cancer Center Hospital East

    Kashiwa-shi, Japan

  • Cancer Institute Hospital of JFCR

    Kōtoku, Japan

  • Kurume University Hospital

    Kurume-shi, Japan

  • Aichi Cancer Center Hospital

    Nagoya, Japan

  • Kindai University Hospital

    Osakasayama-shi, Japan

  • Kanagawa Cancer Center

    Yokohama, Japan

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System - Division of Infectious Diseases

    Seoul, South Korea

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.